Eton Pharmaceuticals, Inc. (ETON) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1248448,
    "name": "Eton Pharmaceuticals, Inc.",
    "stock_name": "Eton Pharmaceuticals, Inc.",
    "full_name": "Eton Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/eton-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "16.81",
    "chg": 1.44,
    "chgp": "9.37%",
    "dir": 1,
    "prev_price": "15.37",
    "mcapval": "476.82",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US29772L1089",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "185.38 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eton-pharmaceuticals-inc-1248448-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Eton Pharmaceuticals Hits New 52-Week High of $23.00, Up 503.61%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eton-pharmaceuticals-hits-new-52-week-high-of-2300-up-50361-3586075",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/EtonPharmaceuti_priceRelatedfactors_3586075.png",
        "date": "2025-10-01 16:43:49",
        "description": "Eton Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its impressive growth in the Pharmaceuticals & Biotechnology sector. Over the past year, the company's stock price surged significantly, despite its current loss-making status and competitive challenges within the industry. Its market capitalization stands at USD 477 million."
      },
      {
        "title": "Is Eton Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-eton-pharmaceuticals-inc-technically-bullish-or-bearish-3547768",
        "imagepath": "",
        "date": "2025-09-20 20:02:42",
        "description": "As of 26 August 2025, the technical trend for Eton Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, supported by bullish signals in both the weekly and monthly MACD, Bollinger Bands, and KST. Daily moving averages also indicate a bullish trend. While the RSI shows no signal, Dow Theory and OBV are mildly bullish on both weekly and monthly time frames. Eton has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 212.35% compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is Eton Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-eton-pharmaceuticals-inc-overvalued-or-undervalued-3544039",
        "imagepath": "",
        "date": "2025-09-20 18:35:56",
        "description": "As of 8 August 2024, the valuation grade for Eton Pharmaceuticals, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, particularly given its negative P/E ratio and poor return metrics. Key ratios include a Price to Book Value of 18.47, an EV to EBITDA of 464.26, and a ROE of -16.07%. \n\nIn comparison to its peers, Eton's valuation metrics are significantly worse; for instance, Esperion Therapeutics, Inc. has a P/E of -4.99 and an EV to EBITDA of -28.92, while Protalix Biotherapeutics, Inc. shows a more attractive P/E of 20.08 and an EV to EBITDA of 9.80. Despite Eton's impressive stock performance, with a 1Y return of 212.35% compared to the S&P 500's 17.14%, the underlying financial metrics suggest that the stock is not supported by its fundamentals...."
      }
    ],
    "total": 8,
    "sid": "1248448",
    "stock_news_url": "https://www.marketsmojo.com/news/eton-pharmaceuticals-inc-1248448"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Eton Pharmaceuticals Hits New 52-Week High of $23.00, Up 503.61%

2025-10-01 16:43:49

Eton Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its impressive growth in the Pharmaceuticals & Biotechnology sector. Over the past year, the company's stock price surged significantly, despite its current loss-making status and competitive challenges within the industry. Its market capitalization stands at USD 477 million.

Is Eton Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 20:02:42

As of 26 August 2025, the technical trend for Eton Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, supported by bullish signals in both the weekly and monthly MACD, Bollinger Bands, and KST. Daily moving averages also indicate a bullish trend. While the RSI shows no signal, Dow Theory and OBV are mildly bullish on both weekly and monthly time frames. Eton has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 212.35% compared to the S&P 500's 17.14%....

Is Eton Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:35:56

As of 8 August 2024, the valuation grade for Eton Pharmaceuticals, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, particularly given its negative P/E ratio and poor return metrics. Key ratios include a Price to Book Value of 18.47, an EV to EBITDA of 464.26, and a ROE of -16.07%. In comparison to its peers, Eton's valuation metrics are significantly worse; for instance, Esperion Therapeutics, Inc. has a P/E of -4.99 and an EV to EBITDA of -28.92, while Protalix Biotherapeutics, Inc. shows a more attractive P/E of 20.08 and an EV to EBITDA of 9.80. Despite Eton's impressive stock performance, with a 1Y return of 212.35% compared to the S&P 500's 17.14%, the underlying financial metrics suggest that the stock is not supported by its fundamentals....

View All News